Nuts and Bolts of Bubble Nasal C P A P

Jen-Tien Wung, M.D., FCCM
Neonatal Intensivist
Professor of Pediatrics
Columbia University Medical Center
New York City (CHONY)

C P A P

Continuous Positive Airway Pressure

- To a spontaneous breathing patient, a positive pressure is applied to the airways throughout the respiratory cycle
- Nasal CPAP has been used at Columbia University NICU since 1973 for >20,000 infants

CPAP

Effects

1. Increases transpulmonary pressure and functional residual capacity (FRC)
2. Prevents alveolar collapse, decreases intrapulmonary shunt and improves lung compliance
3. Conserves surfactant
4. Prevents pharyngeal wall collapse
5. Stabilizes the chest wall
6. Increases airway diameter and splints the airways
7. Splints the diaphragm
8. Stimulates lung growth
9. Bubble CPAP has HFV effect/stochastic resonance



Lung volume, lung weight, and protein and DNA contents at end of study were higher in CPAP-exposed than in control animals (all $P < 0.01$). Strain-induced growth of the immature lung. Zhang S. et al. J. Appl Physiol 1996;81:1471-6


Premature baby
Structural lung immaturity
Surfactant deficiency (RDS)

CPAP

- CPAP is not just for RDS
- CPAP stimulates the growth of premature lung
- We keep the premature infants on CPAP, even on room air CPAP, as long as they are symptomatic (e.g., tachypnea, retraction or apnea & bradycardia.)



Waveform produced at airway with underwater **Bubble CPAP**

Amplitude 2-4 cm H2O,
Frequency 15-30 Hz

Lee K-S et al: Biol Neonate 73: 69-75, 1998



Waveform produced at airway with **HFOV (Sensormedics)**

Set I-time 0.3
Set Frequency 10 Hz

Thome U: J Appl Physiol: 84(5):1520-7, 1998

C P A P

Indication

1. Diseases with low FRC, e.g. RDS, TTN, CPIP, PDA, pulmonary edema, etc.
2. Apnea and bradycardia of prematurity
3. Meconium aspiration syndrome (MAS)
4. Airway closure disease, e.g. bronchiolitis, BPD
5. Tracheomalacia
6. Partial paralysis of diaphragm
7. Respiratory support after extubation

Effect of alveolar radius and surface tension on alveolar stability w/ and w/o surfactant

Law of LaPlace P = 2 T/r



Surfactant reduces surface tension (T). Pressure is equalized in the large and small alveoli



r = 2
T = 2
P = (2 x 2)/2
P = 2

r = 1
T = 1
P = (2 x 1)/1
P = 2

Law of LaPlace : P = 2T/r

P : pressure T : surface tension r : radius





CPAP

Larger alveolus

r = 2

T = 3

P = (2 x 3) / 2

P = 3

Smaller alveolus

r = 1

T = 3

P = (2 x 3) / 1

P = 6

Natural response of surfactant producing cells to birth

Spain CL et.al. Ped. Research, 1987





At onset of breathing, amount of surfactant pool increases significantly

C P A P

Indication

1. Diseases with low FRC, e.g. RDS, TTN, CPIP, PDA, pulmonary edema, etc.
2. Apnea and bradycardia of prematurity
3. Meconium aspiration syndrome (MAS)
4. Airway closure disease, e.g. bronchiolitis, BPD
5. Tracheomalacia
6. Partial paralysis of diaphragm
7. Respiratory support after extubation

Meconium Aspiration Syndrome (MAS)



Meconium Aspiration Syndrome (MAS)



Inspiration

Expiration

Meconium Aspiration Syndrome (MAS)



With CPAP

No CPAP

Waterfall Effect



C P A P

Indication

1. Diseases with low FRC, e.g. RDS, TTN, CPIP, PDA, pulmonary edema, etc.
2. Apnea and bradycardia of prematurity
3. Meconium aspiration syndrome (MAS)
4. Airway closure disease, e.g. bronchiolitis, BPD
5. Tracheomalacia
6. Partial paralysis of diaphragm
7. Respiratory support after extubation


1
2
Air
O_2
3


1
2
Air
O_2
3


Low Flow
Air/O_2 Blender


MEDICAL AIR
USE NO OIL
BEACON MEDICAL PRODUCTS
OXYGEN
USE NO OIL
BEACON MEDICAL PRODUCTS
PRECISION
PURITAN
LITERS OF OXYGEN PER MIN @ 70°F & 760mm Hg

FiO2 vs flow meter readings




1
2
Air
O_2
3

Expiratory Valves

- **Threshold resistors** – the level is determined by the force applied to the surface area of the valve. The pressure generated is independent of flow. (Water bubble CPAP)

- **Variable pressure-flow resistors** – the level of PEEP/CPAP is directly proportional to the product of the gas flow through the orifice of the expiratory pressure valve and the resistance of the valve. (Ventilator)

Bubble-CPAP vs Ventilator-CPAP

All infants with bubble CPAP had:

- a lower minute volume with a **mean reduction in MV of 39%** ($p<0.001$)
- **7 % reduction in respiratory rate** ($p=0.004$)
- With no change in transcutaneous CO_2 and oxygen saturation values

Lee K-S et al: Biol Neonate 73: 69-75, 1998

Physiological Advantage of Bubble versus Ventilator-derived CPAP

- Lower $PaCO_2$
- Higher PaO_2, PH, FRC
- Less V/Q mismatch
- Lower alveolar protein

Bubble Continuous Positive Airway Pressure Enhances Lung Volume and Gas Exchange in Preterm Lambs

Jane Pillow et al. Am J Respir Crit Care Med. 2007 ; 176(1): 63–69.

B-NCPAP vs V-NCPAP

- Randomized crossover study in 18 premature infants (<1500 g) with mild respiratory distress
- Work of breathing, breathing asynchrony, respiratory rate, heart rate, tidal volume, minute ventilation, lung compliance or $TcPCO_2$ was not significantly different
- $TcPO_2$ was higher with B-NCPAP (P=0.01)

Courtney, SE et al.:Journal of Perinatology (2011) 31, 44–50;


1
2
Air
O_2
3

CPAP Devices (Interface)

- Head hood
- Face shield
- Face mask
- Nasal mask
- Nasal prongs – Hudson, Babi-plus nCPAP INCA, Draeger, Fisher&Pakel, SiPAP, Arabella, NeoPAP
- Nasal cannula – *Vapotherm*
- Nasal pharyngeal tube
- Endotracheal tube

Not all CPAP devices are created equal

There is a learning curve for CPAP therapy





Fisher & Pakel



INFANT FLOW™ nCPAP System

A Randomized Controlled Trial of Post-extubation Bubble CPAP vs Infant Flow Driver CPAP in Preterm Infants with RDS

Gupta s et al, J Pediatr 2009;154:645-50

	IFD CPAP	CPAP (F&P)	P value
Failure rate in infants ventilated for ≤14days	28.6(%)	14.1(%)	0.046
Median duration of CPAP support	4 days	2 days	0.031
(+) blood culture	25%	20%	
BPD	30%	20%	0.60

Outcome	IFD CPAP (n=69)	F&P Bubble CPAP(n=71)	Odds ratio (95% CI)
Survival, No BPD	48(66%)	53(75%)	1.23(0.45-3.61)
Death before discharge	0(0%)	*4(5.6%)	
BPD at 36 weeks	21(30%)	14(20%)	0.60(0.28-1.32)
PDA requiring Tx	17(25%)	12(17%)	0.63(0.24-1.63)
Severe IVH/PVL	9 (13.5%)	11(15.6%)	0.96(0.37-2.49)
NEC (Bell stage 2 or higher)	3(4.3%)	5(7.0%)	1.72(0.39-7.49)
ROP requiring Tx	5(7.2%)	4(5.6%)	0.79(0.20-3.07)
Pnemothorax	0	0	

*4 death, 2 from NEC, 2 from sepsis. 3 of these infants had to be reintubated <24 hours after extubation

Nasal Cannula

Vapotherm




OXYGEN
MEDICAL AIR
OXYGEN
USE NO OIL
BEACON
MEDICAL PRODUCTS





F&P Optiflow Junior



Neotech Ram Cannula



RAM Cannula
(NEOTECH Products Inc.)



Mean hypopharyngeal pressures and Gas flow in preterm infants with nasal cannula



Presión Hipofaríngea en prematuros con cánula nasal: Relación con el flujo de gas





Linear regression between flow rate divided by infants'weight and end-expiratory Prp in heated, humidified, high-flow, nasal cannula (HHHFNC) (Prp=0.3+0.7*V'; r2=0.37)

Respiratory Mechanics during NCPAP and HHHFNC at equal distending pressure, Anna Lavizzari et al. Arch Dis Child Fetal Neonatal Published online 30 April 2014

Hypopharyngeal oxygen concentration and pressure delivered by nasal cannula in preterm infants

Alvaro Quintero et al. PAS 3450-3, 2009

Gas Flow	Hypopharynx FiO_2	Hypopharyx Pressure
LPM	Median (Range)	Median (Range)
0.1	0.28 (0.23 – 0.42)	
0.3	0.44 (0.30 - 0.61)	
0.5	0.53 (0.37 - 0.69)	2.7 (1.3 – 13.6)
1	0.69 (0.49 - 0.90)	4.7 (1.3 – 19)
2	0.75 (0.53 - 0.91)	5.4 (4.0 -20.4)



Fig. 1. Study design algorithm for weaning off NCPAP. NC: nasal cannula, NCPAP: nasal continuous positive airway pressure.

Early Human Development 87;2011:205-208





Duration of oxygen exposure and respiratory support in the two groups. Data are expressed in median and interquartile range. Mann–Whitney test was used.

			HHHFNC	nCPAP
Collins, 2013	Extubation Failure	Total	15/67	22/65
(J Pediatr)		28-32 wk	7/37	8/36
		<28 wk	2/30	1/29
	BPD		24/67 (36%)	28/65(43%)
Manley, 2013	Extubation Failure	Total	52/152	39/151
(NEJM)		26-32 wk	26/120	20/120
		<26 wk	26/32	19/31
	BPD		47/152 (31%)	52/151 (34%)

B P D
Proposed New Definition

- Mild: require supplement oxygen at 28 days, but not at 36 weeks PMA
- Moderate: require supplement oxygen for >28 days. At 36 weeks PMA, FiO2 <30%
- Severe: require oxygen >28 days. At 36 weeks PMA, on FiO2 > 30%, IPPV or CPAP

Incidence of BPD

CHONY (6/99 –7/02)

Proposed New Definition

BW(g)	GA(wks)	O_2 (36 wks)	Mild	Mod.	Severe
< 750	25.4±2.0	1 8.3%	31.6%	15.0%	3.3%
750-1000	26.9±1.8	1.4%	16.9%	1.4%	0
1001-1250	29.0±1.8	1.1%	0	1.1%	0
Total	27.4±2.4	5.9%	14.1%	5.0%	0.9%

Sahni et al. J Perinatol 25(1):41-6, 2005.

Nasal Cannulae

- The CPAP and FiO_2 delivered will depend upon the cannulae size, flow, anatomy of nose and space between cannulae and nose
- No safety mechanism to assure that excessive positive pressure is not given
- " ---High–flow nasal cannulae should not be used as a replacement for delivering CPAP." – Kubicka et al. Pediatrics 2008;121:82-88
- "--- easy may not be safe." –Finer, 2005

CPAP Delivery System (Columbia)





$$\text{Resistance} = \frac{\text{Viscosity X Length}}{\text{Radius}^4} \text{ X } \frac{8}{\pi}$$

ET tube ID:	**Resistance (cmH2O/5lpm)**
2.5 mm (length 10 cm)	14.2
3.0 mm (length 12 cm)	6.5
3.5 mm (length 12 cm)	4.3
Hudson CPAP prong size:	
0	2.5
1	1.0
2	1.0
3	0.5
4	0.5
5	0.5

Nasal CPAP

Set up (1)



1. Oxygen blender
2. Flowmeter
   (5-10 LPM)
3. Heated humidifier
4. Thermometer
5. Inspiratory tubing
6. Nasal cannulae
7. Velcro

Nasal CPAP

Set up (2)



8. Manometer (optional)
9. Expiratory tubing
10. A bottle containing a solution of 0.25% acetic acid filled up to a depth of 7 cm. Distal tubing immersed to a depth of 5 cm to create +5 cmH_2O

Bubble CPAP (Portable)



Nasal CPAP
Application (1)

1. Position the baby in supine position with the head elevated about 30 degrees
2. Place a small roll under the baby's neck
3. Put a pre-made hat or stockinet on the baby's head to hold the CPAP tubings

Nasal CPAP
Application (2)

4. **Choose FiO_2 to keep PaO_2 at 50's or O_2 saturation at 85 – 95%**

Nasal CPAP
Application (3)

5. Adjust a flow rate 5-10 lpm to:

a) provide adequate flow to prevent rebreathings CO_2

b) compensate leakage from tubing connectors and around CPAP prongs

c) generate desired CPAP pressure (usually 5 cmH_2O)

6. Keep inspired gas temperature at 37^{O} C

Nasal CPAP
Application (5)

7. Insert the lightweight corrugated tubing (preferrably with heating wire inside) in a bottle of 0.25% acetic acid solution or sterile water filled up to a height of 7 cm. The tube is immersed to a depth of 5 cm to create 5 cmH_2O CPAP as long as air bubbling out of solution


Babi-plus Bubble PAP valve

Fisher & Pakel

Nasal CPAP
Application (6)

8. Choose the proper size of nasal Cannulae

CPAP Cannulae

Size	B.W.
0	< 700g
1	~1000g
2	~ 2000g
3	~ 3000g
4	~ 4000g
5	infant

Nasal CPAP
Application (7)

9. Lubricate the nasal CPAP prongs with sterile water or saline. Place the prongs curved side down and direct into nasal cavities

Nasal CPAP
Application (8)

10. Secure tubings on both sides of the hat with either **safety pins and rubber band** or velcro

Nasal CPAP
Application (9)



11. Secure tubings on both sides of the hat with either safety pins and rubber band or **velcro**




3M
STERILE R
Tegaderm™
NDC 8333-1624-05
Transparent Dressing with Label
Pansement adhésif transparent avec étiquette
Transparentverband mit Dokumentationsstreifen
Medicazione trasparente con etichetta
Apósito Transparente con Etiqueta
Transparant verband met Label
Transparent sårförband med etikett
LATEX


NDC 0003-1879-55
STERILE/ESTERIL
DuoDERM 4 x 4
EXTRA THIN
EXTRA THIN CGF*† DRESSING
APÓSITO DuoDERM® CGF*† EXTRA DELGADO
PANSEMENTS DuoDERM® CGF*† EXTRA-MINCES
For the protection and management of superficial dermal ulcers
Para protección y tratamiento de úlceras dérmicas superficiales
Pour la protection et les soins des ulcères dermiques superficiels





Pressure = Force / Surface Area



Nasal CPAP

Maintenance (1)

1. Observe baby's vital signs, oxygenation and activity
2. Systematically check CPAP systems, inspired gas temperature, air bubbling out of acetic acid solution. Empty condensed water in the circuit
3. Check CPAP prongs position and keep CPAP cannulae off the septum at all times. A snug cap is used to securely hold the tubings in place and using self-adhesive Velcro to keep cannulae away from the septum if necessary

Nasal CPAP
Maintenance (2)

4. Suction nasal cavities, mouth, pharynx and stomach q4h and prn
5. Change the baby's position
6. Change CPAP circuit once a week

Nasal CPAP
Weaning

- CPAP is kept at 5 cmH_2O
- FiO_2 is adjusted to keep PaO_2 in 50's, or oxygen saturation around 90% (85 - 95%)

Weaning CPAP

There are 3 weaning methods

- Off CPAP when the infant is stable on room air without respiratory distress. Resume CPAP if tachypnea, retraction or requires oxygen supplement (preferred method)
- Cycling: where the baby comes off for a period then goes back on -gradually increasing the time off and reducing time on, and reducing the pressure gradually while leaving the baby on.....
- Switch to high flow nasal cannula which provides an unknown pressure equivalent to CPAP -except we don't really know how much.....

Three CPAP weaning methods

M1: Taken ‘OFF’ CPAP with the view to stay ‘OFF’

M2: Cycled on and off CPAP with incremental time ‘OFF’.

M3: As with M2, cycled on and off CPAP but during ‘OFF’ periods were supported by 2 mm nasal cannula at a fl ow of 0.5 l/min.

Arch Dis Child Fetal Neonatal Ed published online May 18, 2012

Methods of weaning preterm babies <30 weeks gestation off CPAP: a multicentre randomised controlled trial

	M1 (n=56)	m² (n=69)	M3 (n=52)	Sig
Time of wean‡	11.3±0.8	16.8±1.0*	19.4±1.3*	p<0.0001
Total days CPAP	24.4±0.1	38.6±0.1*	30.5±0.1*	p<0.0001
CGA OFF CPAP	31.9±0.1	34.1±0.1*	32.8±0.2*	p<0.0001
Oxygen duration‡	24.1±1.5	45.8±2.2*	34.1±2.0*	p<0.0001
BPD	7/56 (12.5%)	29/69 (42%)†	10/52 (19%)	p=0.011
Length of Admission	58.5±0.1	73.8±0.1*	69.5±0.1*	p<0.0001
CGA at D/C#	35.8±0.1	36.9±0.1*	36.9±0.1*	p<0.0001

CGA: corrected GA;

Arch Dis Child Fetal Neonatal Ed published online May 18, 2012

Nasal CPAP
Discontinued

- No tachypnea or retraction
- No apnea and bradycardia
- FiO_2 is usually room air

Nasal CPAP
Complications (1)

- Nasal obstruction from secretions or improper application of nasal prongs
- Gastric distention from swallowing air, especially in infants on aminophylline or caffeine
- Nasal septum erosion or necrosis
- Fluctuating FiO_2
- Air leak: <5%, usually occurs during acute phase

Nasal CPAP
Complications (2)

- Pneumothorax, if occurs, usually occurs within the first few days of use, not after a week. Furthermore, pneumothorax is generally less severe and less frequent in infants on CPAP compared to intubated infants on mechanical ventilation.
- Most of complications are preventable
- The majority of the problems can be attributed to inappropriate use, wrong device or a lack of training and experience

INFANT FLOW™ mask






WARNING


MC SUSAN

Feeding on CPAP

Baby may feed at breast


395 gms , On CPAP since birth


3 months old
BW 395gm, on CPAP for 82 days

480gm, 24 weeks, on CPAP since birth

CPAP

Novel Application

- Mechanical ventilation via nasal CPAP cannulae
- Preferably in SIMV, A/C or pressure support mode. Infant Star Sync is not available anymore.

  (using Servo i with NAVA).
- PIP: 15-20 cmH_2O, PEEP: 5 cmH_2O
- Indications:

✓ Frequent A&B

✓ High $PaCO_2$

✓ Laborious breathings


Trigger
−10
0
20
40
60
Paw
cm H2O
Alarm
man.
Insp.
Tin 0.50 s
Tex 1.0 s
fset 40 bpm
I:E 1: 2.0
O2conc 21 %
VTin 8.0 L/min
VTex 8.0 L/min
Pinsp 20 cmH2O
PEEP 5.0 cmH2O
Trig 1.0
Confirm
Cal.
Config.
O2-Conc.%
50
60
40
70
30
80
25
90
21
100
Tin
0,6
0,4
0,8
0,3
1,0
0,2
1,5
0,1
2 s
Tex
1,0
0,8
2
0,6
5
0,4
15
0,2
30 s
Vent.
Mode
Vent.
Options
Insp. Flow V̇
6
8
4
10
2
20
1
30 L/min
Pinsp
40
30
50
20
60
10
70
5
80 cm H2O
PEEP/CPAP
6
10
3
15
0
25 cm H2O


MAQUET
MSCHONY
MAQUET
Servo-i
36.7

Edi Catheter positioning procedure
Position and Edi signal






MAQUET
GETINGE GROUP
NIV NAVA
Admit patient
Nebulizer
Status
30 cmH2O
30 l/min comp.
-30
60 ml comp.
60 µV
05-15 16:17
Ppeak (cmH2O)
19
30
PEEP (cmH2O)
4
RR (b/min)
84
100
20
O2 (%)
40
Ti/Ttot
0.53
MVe (l/min)
3.4
5.0
0.40
VTi (ml)
45
VTe (ml)
45
Leakage (%)
87
Edi peak (µV)
19
Edi min (µV)
3.1
Alarm profile
Save
Trends
i
Neural access
Quick access
Menu
Main screen
Additional settings
O2 conc.
40
%
21
100
PEEP
5
cmH2O
2
NAVA level
1.0
Additional values


NDC 0003-1879-55
STERILE/ESTERIL
DuoDERM 4 x 4
EXTRA THIN
EXTRA THIN CGF*† DRESSING
APÓSITO DuoDERM® CGF*† EXTRA DELGADO
PANSEMENTS DuoDERM® CGF*† EXTRA-MINCES
For the protection and management of superficial dermal ulcers
Para protección y tratamiento de úlceras dérmicas superficiales
Pour la protection et les soins des ulcères dermiques superficiels


1
2
3
4
5
6
7
8


1
2
3
4
5
6
7
8
9
10


0
1
2
3
4
5
6
7
8
cm
CPAP
SIZE 2
1250-2000g
CANNULAIDE®
INFANT CPAP
NASAL SEAL
Reorder CA102
1
Lot 20031001
May 2005
For use by or on order of a licensed physician only.
For single use only.
Beevers Mfg & Supply
503-472-9055
Rev C 2003 09 30

Mechanical Ventilation

Indications

1. Marked retractions on CPAP (not due to nasal obstruction)
2. Frequent apnea and bradycardia on CPAP
3. $PaO_2 < 50$ mm Hg with $FiO_2 > 60\%$
4. $PaCO_2 > 70$ mm Hg (except 1^{st} ABGS)
5. Intractable metabolic acidosis
   (BD > 10 meq/L after Rx with $NaHCO_3$)
6. Other (Cardiovascular collapse, Neuromuscular disorder, Congenital diaphragmatic hernia, or for Surgery, MRI, Cardiac catheterization, etc.)

The Columbia Experience with CPAP

Morgan Stanley
Children's Hospital
of NewYork-Presbyterian
Columbia University Medical Center

The Columbia Experience (1997-1999)

A retrospective database review for a cohort of all live inborn VLBW infants (BW 500-1500g) born between Jan 1, 1997 and Dec 31, 1999 (three calendar years).

- 320 infants were divided into three groups :

1) CPAP only group (n = 230): received only bubble NCPAP for respiratory support during the first 24 hrs of life.

2) CPAP failed group (n = 60): Infants managed initially with NCPAP who required intubation within 24 hrs of birth.

3) Vent only group (n = 30): Infants requiring intubation immediately following birth.

The Columbia Experience (1997-1999)

BW(gm)	CPAP Only(%)	CPAP/ IMV(%)	IMV (%)	Total	Expired (%)
500-750	21(31.8)	26(39.4)	19(28.8)	66	11(16.7)
751-1000	58(69)	17(20.2)	9(10.7)	84	6(7.1)
1001-1250	59(85.5)	9(13)	1(1.4)	69	0
1251-1500	92(91)	8(7.9)	1(1)	101	7(6.9)
Total	230(71.9)	60(18.8)	30(9.4)	320	24(7.5)


100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
<750g
751-1000g
1001-1250g
1251-1500g
Total
MV
CPAP Failure
CPAP only

BPD
(Required oxygen suplement at 36 wks PCA)

BW(gm)	CPAP only	CPAP/IMV	IMV	Total
500-750	0/21	1/26	3/19	4/66
751-1000	1/58	0/17	0/9	1/84
1001-1250	0/59	0/9	0/1	0/69
1251-1500	1/92	1/8	0/1	2/101

Intraventricular Hemorrhage (IVH Grade III-IV)

BW(gm)	CPAP only	CPAP/IMV	IMV	Total
500-750	1/21	3/26	4/19	8/66
751-1000	0/58	0/17	0/9	0/84
1001-1250	1/59	0/9	0/1	1/69
1251-1500	0/92	1/8	0/1	1/101

Retinopathy of Prematurity (ROP Stage 3-4)

BW(gm)	CPAP only	CPAP/IMV	IMV	Total
500-750	4/21	5/26	3/19	12/66
751-1000	0/58	0/17	0/9	0/84
1001-1250	0/59	0/9	0/1	0/69
1251-1500	0/92	0/8	0/1	0/101

Mortality before Discharge

BW(gm)	CPAP only	CPAP/IMV	IMV	Total
500-750	0/21	3/26	8/19	11/66
751-1000	1/58	3/17	2/9	6/84
1001-1250	0/59	0/9	0/1	0/69
1251-1500	3/92	3/8	1/1	7/101

The strategy of

Early nasal CPAP therapy first and

Surfactant replacement only for rescue

does not jeopardize outcome of very low birth weight infants

CURPAP study

(R Plavka, U Simeoni et al. ESPR: Arch Dis Child 2008;93(Suppl II):A34)

- **Question**: is the prophylactic administration of surfactant superior to early rescue treatment in spontaneously breathing infants supported on nCPAP, in reducing the need for mechanical ventilation, during the first 5 days of life?
- **Population**: 25-28 weeks infants (European multicentre, n=24)
- **Outcome**:

  . Duration of mechanical ventilation during the first 5 days of life

  . Mortality, pulmonary and neurological morbidity

CURPAP study: method



CURPAP study: preliminary results

Parameter	nCPAP	CURPAP
Gestational age (median in weeks)	27	27
Birth weight (g)	913 ± 200	967 ± 221
Antenatal steroids	98%	96%
CPAP failure => mechanical ventilation	**31%**	**33%**
Pneumothorax	**1%**	**6.7%***
Mortality	10.7%	8.6%
BPD	22%	23.8%

50% rescue surfactant
(median =240 min of age)

Summary of the CURPAP study

- Prophylactic surfactant is **not** superior to early rescue surfactant therapy after CPAP
- Surfactant was halved in the nCPAP group
- Outcome was really good in both arms

	500-1000g	1000-1500g	1500-2000g	2000-2500g
BPD Rate (O_2 at 36 wks)	57%	19%	10%	17%
Early CPAP Rate	19%	48%	72%	75%
Early CPAP Failure Rate	67%	38%	24%	24%
Vent at anytime	86%	51%	25%	21%

Source: VON 2006, CDC Statistics 2006 & 2005

NICU Quality and Outcome, 2013

501 – 1500g

	MSCH	Vermont Oxford
Incidence of BPD	7.7%	34.6%
Nosocomial infection	5.8%	13.4%
Incidence of IVH	13.5%	25.9%
Incidence of Severe ROP	6.3%	7.8%
Incidence of NEC	5.5%	6.7%
Neonatal Mortality rate	9.5%	15.0%

Reasons for different results in previous CPAP studies

- The difference in devices used and experiences
- The difference in criteria of CPAP failure
- Studies did not show significant reduction of BPD because CPAP therapy was discontinued too early to take advantage of stimulation of lung growth.

Do not brand a form of therapy as useless,

when in reality it was only inappropriately applied.


I Love My
CPAP


I want Nasal CPAP, Please!


Thank You for your attention

VON Data Presentation: 10/21/2009

* Focus on BW 501-1000 Gm Infants
* 2 Subgroups by BW
  - 501-750 Gm
  - 751-1000 Gm
* 2 Subgroups by Time Span
  - 1st period: 1998-2002
  - 2nd period: 2003-2008
* Peek at characteristic/outcomes of "Type C" centers
* A quick look at the Expanded Data results.

CPAP Before ETT Vent
501-1000 Gm



Surfactant at Any Time
501-1000 Gm



Severe IVH (3+4)
501-1000 Gm



Cystic PVL



Severe ROP
501-750 Gm



Oxygen at 36 weeks GA, <33 W (CLD)
501-1000 Gm



Survival w/o Specified Morbidities
501-1000 Gm



Case-Cohort Study
Boston-Columbia

- Linda VanMarter et al.: Do Clinical Markers of Barotrauma and Oxygen Toxicity Explain Interhospital Variation in Rates of Chronic Lung Disease?

- 441 infants born at 500 to 1500 g birth weight Columbia (N=100) vs Boston Beth Israel and Brigham (N=341)

VanMarter LJ: Pediatrics 105 (6): 1194-1201, 2000

Center-Specific Respiratory Management



Hospital Specific Rates of CLD at 36 weeks PMA by Birth Weight and Gestational Age



Hospital Specifc Rates of CLD at 36 weeks PMA by Ethnicity



	CHONY	Boston
CPAP	63 %	11 % *
Ventilation	29 %	75 % *
# days MV	13 d	27 d *
Surfactant	10 %	45 % *
Indomethacin	2 %	28 % *
Sedation	0 %	46 % *
Postnatal Steroids	3 %	4 %
BPD	4 %	22 % *
Mortality	9 %	10 %

* P < 0.05

(No significant differences in IVH, PVL, NEC or ROP)

Van Marter et al, Pediatr 2000; 105:1194-1201

Neurodevelopmental Outcome

Sanocka U et al (PAS 2002) assessed neurodevelopment at age 6-8 years in two cohorts VLBW infants (n=218), one from New York & one from Boston, that differed in their respiratory management

Long-term Neurocognitive Development



- Not all CPAP devices are created equal
- There is a learning curve for CPAP therapy
- The more you do it, the better you get at it. And the better you get, the easier you will feel.

Babi-plus nCPAP

Size 7 – size 0

Made of silicone, not PVC.

latex-free


Babi-plus nCPAP System

Concentration of saturated phosphatidylcholine (DPPC) in neonatal lungs by gestational age